488 reports of this reaction
1.6% of all ISONIAZID reports
#15 most reported adverse reaction
HEPATOTOXICITY is the #15 most commonly reported adverse reaction for ISONIAZID, manufactured by CMP Pharma, Inc.. There are 488 FDA adverse event reports linking ISONIAZID to HEPATOTOXICITY. This represents approximately 1.6% of all 29,971 adverse event reports for this drug.
Patients taking ISONIAZID who experience hepatotoxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOTOXICITY is a less commonly reported adverse event for ISONIAZID, but still significant enough to appear in the safety profile.
In addition to hepatotoxicity, the following adverse reactions have been reported for ISONIAZID:
The following drugs have also been linked to hepatotoxicity in FDA adverse event reports:
HEPATOTOXICITY has been reported as an adverse event in 488 FDA reports for ISONIAZID. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOTOXICITY accounts for approximately 1.6% of all adverse event reports for ISONIAZID, making it a notable side effect.
If you experience hepatotoxicity while taking ISONIAZID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.